Trevena Reports Fourth Quarter 2023 Results and Provides Corporate Update

TRV045, novel S1P receptor modulator for chronic pain and epilepsy, advances toward important milestones in both non-clinical and clinical studies...

Related Keywords

United States ,Carrie Bourdow ,Bob Yoder ,Company Contact ,Epilepsy Therapy Screening Program ,Company Annual Report On Form ,Nasdaq ,National Institutes Of Health ,Lifesci Advisors ,Exchange Commission ,Trevena Inc ,Trevena Medical Information Contact Center ,Recent Corporate ,Supported Epilepsy Therapy Screening Program ,Fourth Quarter ,Nobel Prize ,National Institutes ,Investigational New Drug Application ,Important Safety Information ,Induced Hyperalgesia ,Private Securities Litigation Reform Act ,Risk Factors ,Annual Report ,Quarterly Reports ,Sci Advisors ,Chief Business ,Months Ended Dec ,Ended Dec ,